Status
Conditions
Treatments
About
This study is to investigate breath analysis (breath metabolomics) combined with established bioinformatic tools as a platform for companion diagnostics.
Full description
Therapeutic drug monitoring (TDM) is defined as measuring concentrations of a drug at one or more time points in a biological matrix after a dose. The purpose of TDM is to individualize the drug dose to achieve maximum efficacy and at the same time minimize toxicity. The concept of TDM could potentially be even more valuable if in addition to drug concentrations, other drug-regulated and drug-related metabolites could be included in the models to define optimal dosage. There exists a clinical need to stratify patients with better precision to improve current clinical and therapeutic management. Breath analysis offers an opportunity to non-invasively retrieve relevant information on the ongoing internal biochemical processes, as well as to monitor the respiratory system itself. For breath analysis, a Secondary Electrospray ionization - mass spectrometry (SESI-MS) breath analysis platform will be used to capture disease-related, drug-regulated and drug-related metabolites (breath metabolomics) in exhaled breath. This information, retrieved in parallel to standard of care clinical co-variates, could have the potential to provide a more personalized therapeutic management of patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Additional inclusion criteria for respiratory disease population:
Additional inclusion criteria for neurological disease population:
Additional inclusion criteria for T1D disease population:
Exclusion criteria
Additional exclusion criteria for respiratory disease population:
Additional exclusion criteria for neurological disease population:
Additional exclusion criteria for T1D population:
3,600 participants in 12 patient groups
Loading...
Central trial contact
Mélina Richard; Pablo Sinues, Prof. Dr.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal